A New Discriminative Criterion for the Development of Franz Diffusion Tests for Transdermal Pharmaceuticals

PURPOSE. In vitro skin/membrane permeation profiling of topical pharmaceuticals is an important overall quality attribute in the evaluation of product consistency and it is also used for IVIVR (in vitro - in vivo relationship) purposes in product development and change control. Franz diffusion cell...

Full description

Bibliographic Details
Main Authors: Bram Baert, Jente Boonen, Christian Burvenich, Nathalie Roche, Filip Stillaert, Phillip Blondeel, Jan Van Boxclaer, Bart De Spiegeleer
Format: Article
Language:English
Published: Canadian Society for Pharmaceutical Sciences 2010-07-01
Series:Journal of Pharmacy & Pharmaceutical Sciences
Online Access:https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/6737
id doaj-359015863c4040ada93104d5494a1355
record_format Article
spelling doaj-359015863c4040ada93104d5494a13552020-11-25T03:44:23ZengCanadian Society for Pharmaceutical SciencesJournal of Pharmacy & Pharmaceutical Sciences1482-18262010-07-0113210.18433/J3WS33A New Discriminative Criterion for the Development of Franz Diffusion Tests for Transdermal PharmaceuticalsBram BaertJente BoonenChristian BurvenichNathalie RocheFilip StillaertPhillip BlondeelJan Van BoxclaerBart De Spiegeleer0Prof. Dr. Apr.PURPOSE. In vitro skin/membrane permeation profiling of topical pharmaceuticals is an important overall quality attribute in the evaluation of product consistency and it is also used for IVIVR (in vitro - in vivo relationship) purposes in product development and change control. Franz diffusion cell (FDC) experiments are emerging as a generally accepted methodology in this field, where the choice of operational conditions requires a data-supported justification towards the discriminating power of the test. A response function is therefore proposed to objectively quantify the discriminating power. METHODS. We evaluated the usefulness of the proposed response function by studying one of the operational conditions, i.e. the influence of receptor medium composition, on the FDC in vitro penetration behaviour of the model compound testosterone formulated in four different topical preparations, using both artificial membranes and dermatomed human skin. RESULTS. From the obtained cumulative amount of testosterone in the receptor fluid versus time curves, the permeability coefficient Kp of testosterone from each formulation was calculated. The evaluation of the discriminating power of the different media was performed using our new objective response function based upon an equal spread criterion of normalised Kp values. CONCLUSION. We demonstrated significant differences in discriminating power between the different media used, with the overall best results obtained with hydroxypropyl-β-cyclodextrine (HPBCD) containing media. The proposed new criterion was found to be useful for the rational design of an in vitro diffusion test for transdermal pharmaceuticals.https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/6737
collection DOAJ
language English
format Article
sources DOAJ
author Bram Baert
Jente Boonen
Christian Burvenich
Nathalie Roche
Filip Stillaert
Phillip Blondeel
Jan Van Boxclaer
Bart De Spiegeleer
spellingShingle Bram Baert
Jente Boonen
Christian Burvenich
Nathalie Roche
Filip Stillaert
Phillip Blondeel
Jan Van Boxclaer
Bart De Spiegeleer
A New Discriminative Criterion for the Development of Franz Diffusion Tests for Transdermal Pharmaceuticals
Journal of Pharmacy & Pharmaceutical Sciences
author_facet Bram Baert
Jente Boonen
Christian Burvenich
Nathalie Roche
Filip Stillaert
Phillip Blondeel
Jan Van Boxclaer
Bart De Spiegeleer
author_sort Bram Baert
title A New Discriminative Criterion for the Development of Franz Diffusion Tests for Transdermal Pharmaceuticals
title_short A New Discriminative Criterion for the Development of Franz Diffusion Tests for Transdermal Pharmaceuticals
title_full A New Discriminative Criterion for the Development of Franz Diffusion Tests for Transdermal Pharmaceuticals
title_fullStr A New Discriminative Criterion for the Development of Franz Diffusion Tests for Transdermal Pharmaceuticals
title_full_unstemmed A New Discriminative Criterion for the Development of Franz Diffusion Tests for Transdermal Pharmaceuticals
title_sort new discriminative criterion for the development of franz diffusion tests for transdermal pharmaceuticals
publisher Canadian Society for Pharmaceutical Sciences
series Journal of Pharmacy & Pharmaceutical Sciences
issn 1482-1826
publishDate 2010-07-01
description PURPOSE. In vitro skin/membrane permeation profiling of topical pharmaceuticals is an important overall quality attribute in the evaluation of product consistency and it is also used for IVIVR (in vitro - in vivo relationship) purposes in product development and change control. Franz diffusion cell (FDC) experiments are emerging as a generally accepted methodology in this field, where the choice of operational conditions requires a data-supported justification towards the discriminating power of the test. A response function is therefore proposed to objectively quantify the discriminating power. METHODS. We evaluated the usefulness of the proposed response function by studying one of the operational conditions, i.e. the influence of receptor medium composition, on the FDC in vitro penetration behaviour of the model compound testosterone formulated in four different topical preparations, using both artificial membranes and dermatomed human skin. RESULTS. From the obtained cumulative amount of testosterone in the receptor fluid versus time curves, the permeability coefficient Kp of testosterone from each formulation was calculated. The evaluation of the discriminating power of the different media was performed using our new objective response function based upon an equal spread criterion of normalised Kp values. CONCLUSION. We demonstrated significant differences in discriminating power between the different media used, with the overall best results obtained with hydroxypropyl-β-cyclodextrine (HPBCD) containing media. The proposed new criterion was found to be useful for the rational design of an in vitro diffusion test for transdermal pharmaceuticals.
url https://journals.library.ualberta.ca/jpps/index.php/JPPS/article/view/6737
work_keys_str_mv AT brambaert anewdiscriminativecriterionforthedevelopmentoffranzdiffusiontestsfortransdermalpharmaceuticals
AT jenteboonen anewdiscriminativecriterionforthedevelopmentoffranzdiffusiontestsfortransdermalpharmaceuticals
AT christianburvenich anewdiscriminativecriterionforthedevelopmentoffranzdiffusiontestsfortransdermalpharmaceuticals
AT nathalieroche anewdiscriminativecriterionforthedevelopmentoffranzdiffusiontestsfortransdermalpharmaceuticals
AT filipstillaert anewdiscriminativecriterionforthedevelopmentoffranzdiffusiontestsfortransdermalpharmaceuticals
AT phillipblondeel anewdiscriminativecriterionforthedevelopmentoffranzdiffusiontestsfortransdermalpharmaceuticals
AT janvanboxclaer anewdiscriminativecriterionforthedevelopmentoffranzdiffusiontestsfortransdermalpharmaceuticals
AT bartdespiegeleer anewdiscriminativecriterionforthedevelopmentoffranzdiffusiontestsfortransdermalpharmaceuticals
AT brambaert newdiscriminativecriterionforthedevelopmentoffranzdiffusiontestsfortransdermalpharmaceuticals
AT jenteboonen newdiscriminativecriterionforthedevelopmentoffranzdiffusiontestsfortransdermalpharmaceuticals
AT christianburvenich newdiscriminativecriterionforthedevelopmentoffranzdiffusiontestsfortransdermalpharmaceuticals
AT nathalieroche newdiscriminativecriterionforthedevelopmentoffranzdiffusiontestsfortransdermalpharmaceuticals
AT filipstillaert newdiscriminativecriterionforthedevelopmentoffranzdiffusiontestsfortransdermalpharmaceuticals
AT phillipblondeel newdiscriminativecriterionforthedevelopmentoffranzdiffusiontestsfortransdermalpharmaceuticals
AT janvanboxclaer newdiscriminativecriterionforthedevelopmentoffranzdiffusiontestsfortransdermalpharmaceuticals
AT bartdespiegeleer newdiscriminativecriterionforthedevelopmentoffranzdiffusiontestsfortransdermalpharmaceuticals
_version_ 1724515362821636096